España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

waidden pharma s.l. - ibuprofeno lisina - polvo para suspensiÓn oral - 600 mg - ibuprofeno lisina 600 mg - ibuprofeno

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

v.m.d. nv - butorfanol tartrato - soluciÓn inyectable - butorfanol tartrato 14,58mg - butorfanol - caballos; perros; gatos

Argentina - español - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

trb pharma s.a. - diclofenac - comprimidos recubiertos - diclofenac sodico 50.00 mg; pridinol mesilato 4.00 mg

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

laboratorio farmaceutico medical s.a. - droguerÍa - diclofenaco dietilamonio; - gel - por sobre 100.00 g - - diclofenaco

Guatemala - español - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

krona internacional - comprimido - 5 mg

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

laboratorio farmaceutico medical s.a. - gel

Venezuela - español - Instituto Nacional de Higiene

laboratorios elmor, s.a. - diclofenaco potasico - comprimidos con recubrimiento enterico - 50 mg

Unión Europea - español - EMA (European Medicines Agency)

instituto grifols s.a. - la inmunoglobulina humana normal - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - los sueros inmunes e inmunoglobulinas, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.